Intellia Therapeutics : Termination of Material Agreement - Form 8-K

Item 1.02 Termination of a Material Definitive Agreement.

On March 19, 2024, Intellia Therapeutics, Inc. (the "Company" or "Intellia") notified Regeneron Pharmaceuticals, Inc. ("Regeneron") that the Company is opting out of its Factor IX Co-Developmentand Co-FundingAgreement (the "Co-CoAgreement"), which the Company and Regeneron entered into in May 2020. The Co-CoAgreement will terminate 180 days after Intellia provided written notice to Regeneron, and the Company will continue to have obligations under the Co-CoAgreement related to the co-developmentof gene editing products directed to factor IX until the effective date of termination. Upon termination, the Company will no longer be obligated for sharing 35% of the development costs, or be entitled to receive 35% of the profits, for gene editing products directed to factor IX under the Co-CoAgreement. In addition, after termination of the Co-CoAgreement Intellia would continue to support Regeneron with the development of gene editing products directed to factor IX, as applicable, under the License and Collaboration Agreement between the Company and Regeneron, dated April 11, 2016, as amended (the "LCA"), and the LCA will control the parties' obligations to develop and commercialize gene editing products directed to factor IX, including any milestone payments and royalties that would be owed to the Company if Regeneron develops and commercializes such products and the intellectual property licenses and other rights related to such products. Under the LCA, Intellia may be eligible to receive up to $320.0 million in milestone payments and royalties in the high-single digits to low teens, which royalties are potentially subject to various reductions, offsets and upstream payment obligations. The termination of the Co-CoAgreement does not affect any other target or programs that are the subject of the Company's collaboration with Regeneron under the LCA or any other co-developmentand co-fundingagreement with Regeneron.

The foregoing summary is qualified in its entirety by reference to the form of Co-Developmentand Co-PromotionAgreement which the Company filed as Exhibit 10.16 to its Annual Report on Form 10-Kfor the year ending December 31, 2023.

Forward Looking Statements.

This Current Report on Form 8-Kcontains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, but are not limited to, express or implied statements regarding the Company's beliefs and expectations regarding: the termination of the Co-CoAgreement and the development of gene editing products directed to factor IX under the LCA, including the Company's obligations under the LCA, Regeneron's continued development of such products, and potential milestone payments and royalties related to such products. Any forward-looking statements in this Current Report on Form 8-Kare based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to the Company's ability to protect and maintain its intellectual property position; risks related to the Company's relationship with third parties, including Regeneron; and risks related to the Company's or its collaborators' ability to develop and commercialize product candidates successfully, including gene editing products directed to factor IX. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent annual report on Form 10-K,as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All information in this Current Report on Form 8-Kis as of the date of this report, and the Company undertakes no duty to update this information unless required by law.